PDCD1 and cancer: PD-1 targeted immunotherapy is one of the most commonly used immunotherapies for cancer, and PD-1 and T-cell immunoglobulin and ITIM domain may be preferred targets for immune checkpoint inhibitor immunotherapy (32).